Tenaya Therapeutics annual free cash flow
2020
2021
2022
2023
2024
2025
Tenaya Therapeutics Free Cash Flow (FCF) History (TNYA)
Tenaya Therapeutics reported −$68.9M in free cash flow for fiscal 2025, an increase of $22.6M from the previous fiscal year.
View full Tenaya Therapeutics company overviewTenaya Therapeutics free cash flow by year
| Fiscal year | Period ended | Free cash flow | Change | Growth | FCF margin |
|---|---|---|---|---|---|
| 2025 | 2025-12-31 | −$68.9M | $22.6M | — | — |
| 2024 | 2024-12-31 | −$91.5M | $11.8M | — | — |
| 2023 | 2023-12-31 | −$103.3M | $21.7M | — | — |
| 2022 | 2022-12-31 | −$125.1M | −$39.1M | — | — |
| 2021 | 2021-12-31 | −$85.9M | −$40.7M | — | — |
| 2020 | 2020-12-31 | −$45.2M | — | — | — |
Tenaya Therapeutics quarterly free cash flow
Q3.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Free cash flow | Change | YoY growth | FCF margin |
|---|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | −$3.7M | $12.0M | — | −334.32% |
| Q1 2026 | 2026-03-31 | −$19.2M | $4.3M | — | −8553.33% |
| Q4 2025 | 2025-12-31 | −$14.0M | $4.6M | — | — |
| Q3 2025 | 2025-09-30 | −$15.6M | $4.4M | — | — |
| Q2 2025 | 2025-06-30 | −$15.8M | $7.9M | — | — |
| Q1 2025 | 2025-03-31 | −$23.5M | $5.7M | — | — |
| Q4 2024 | 2024-12-31 | −$18.6M | $3.7M | — | — |
| Q3 2024 | 2024-09-30 | −$20.0M | $3.6M | — | — |
| Q2 2024 | 2024-06-30 | −$23.7M | $2.7M | — | — |
| Q1 2024 | 2024-03-31 | −$29.2M | $1.7M | — | — |
| Q4 2023 | 2023-12-31 | −$22.3M | $1.2M | — | — |
| Q3 2023 | 2023-09-30 | −$23.6M | $8.0M | — | — |
| Q2 2023 | 2023-06-30 | −$26.4M | $6.2M | — | — |
| Q1 2023 | 2023-03-31 | −$30.9M | $6.4M | — | — |
| Q4 2022 | 2022-12-31 | −$23.5M | $5.4M | — | — |
| Q3 2022 | 2022-09-30 | −$31.6M | −$10.0M | — | — |
| Q2 2022 | 2022-06-30 | −$32.6M | −$17.4M | — | — |
| Q1 2022 | 2022-03-31 | −$37.4M | −$17.2M | — | — |
| Q4 2021 | 2021-12-31 | −$28.9M | −$19.2M | — | — |
| Q3 2021 | 2021-09-30 | −$21.7M | — | — | — |
| Q2 2021 | 2021-06-30 | −$15.3M | — | — | — |
| Q1 2021 | 2021-03-31 | −$20.1M | — | — | — |
| Q3 2020 | 2020-09-30 | −$9.7M | — | — | — |
Tenaya Therapeutics free cash flow growth trends
Over the last five reported fiscal years, free cash flow declined from −$45.2M to −$68.9M, a net decrease of $23.7M. Tenaya Therapeutics's latest reported quarter, Q2 2026, generated −$3.7M in free cash flow, an increase of $12.0M year over year.
About the metric
What free cash flow means
Free cash flow is the cash a company generates from operations after capital expenditures. Positive FCF can fund dividends, buybacks, debt repayment, or reinvestment; negative FCF means capital spending exceeded operating cash flow for that period.
Calculation and source
How free cash flow is calculated
TickerStat calculates free cash flow as SEC-reported operating cash flow minus capital expenditures. FCF margin equals free cash flow divided by revenue. Fiscal periods can differ from calendar years, so the tables include exact period-end dates.
Review Tenaya Therapeutics filings at SEC.gov ↗